Who are Lipid-Based Artificial Tear's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Meticel Ofteno® 0.5%, Tears Naturale, methylcellulose 0.5%, TJO-018 (HA 0.15%), Retaine™, Sodium Hyaluronate Ophthalmic 0.4%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lipid-based-artificial-tear.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Lipid-Based Artificial Tear — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lipid-Based Artificial Tear (Lipid-Based Artificial Tear) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Artificial tear / Ocular lubricant. Area: Ophthalmology.

marketed Artificial tear / Ocular lubricant Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Lipid-Based Artificial Tear (Lipid-Based Artificial Tear) — University of Seville. A lipid-based formulation that mimics the natural tear film to provide lubrication and protect the ocular surface.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Lipid-Based Artificial Tear TARGET	Lipid-Based Artificial Tear	University of Seville	marketed	Artificial tear / Ocular lubricant
Meticel Ofteno® 0.5%	Meticel Ofteno® 0.5%	Laboratorios Sophia S.A de C.V.	marketed	Artificial tear / Ocular lubricant
Tears Naturale	Tears Naturale	Andover Research Eye Institute	marketed	Artificial tear / Ocular lubricant
methylcellulose 0.5%	methylcellulose 0.5%	Clinica Oftamologica Zona Sul	marketed	Artificial tear / Ocular lubricant
TJO-018 (HA 0.15%)	TJO-018 (HA 0.15%)	Taejoon Pharmaceutical Co., Ltd.	marketed	Artificial tear / Ocular lubricant	Ocular surface (non-receptor mediated)
Retaine™	Retaine™	Ocusoft, Inc.	marketed	Artificial tear / ocular lubricant
Sodium Hyaluronate Ophthalmic 0.4%	Sodium Hyaluronate Ophthalmic 0.4%	Laboratorios Sophia S.A de C.V.	marketed	Artificial tear / Ocular lubricant

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Artificial tear / Ocular lubricant class)

Laboratorios Sophia S.A de C.V. · 7 drugs in this class
Allergan · 3 drugs in this class
University of Waterloo · 2 drugs in this class
University of California, Berkeley · 2 drugs in this class
Bp Consulting, Inc · 1 drug in this class
Chong Kun Dang Pharmaceutical · 1 drug in this class
Clinica Oftamologica Zona Sul · 1 drug in this class
Fundação Altino Ventura · 1 drug in this class
Medical University of South Carolina · 1 drug in this class
Ocuwize LTD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lipid-Based Artificial Tear — Competitive Intelligence Brief. https://druglandscape.com/ci/lipid-based-artificial-tear. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing